Backgrounds/Aims: Hepatocellular carcinoma (HCC) recurrence following hepatic resection (HR) and liver transplantation (LT) remains a great concern. We assessed the antitumor effects of metformin in patients treated with sorafenib for HCC recurrence after HR or LT. Methods: The two clinical retrospective studies involved metformin therapy of 304 HR patients and 74 LT recipients who were treated with sorafenib. Results: In the study involving patients who had undergone HR, death occurred in 245 of the 304 patients (80.6%) during a median follow-up of 10.2 months after sorafenib administration. The metformin HR group (group 1; n=40) showed no prognostic difference in progression-free and overall survival rates compared with the all-HR control group (group 3; n=241) and propensity score-matched HR control group (group 4; n=80). In the clinical study of recipients exposed to LT, death occurred in 62 of the 74 patients (83.8%) during a median follow-up of 13.6 months (range: 3-76 months) after sorafenib administration. The metformin LT group (group 5; n=14) showed no prognostic difference in progression-free and overall survival rates compared with the all-LT control group (group 7; n=43) and propensity score-matched LT control group (group 8; n=28). 
INTRODUCTION
HCC recurrence after HR or LT is initially treated with various locoregional therapies; however, tumor progression renders such treatments refractory. Thus, a considerable number of patients undergo systemic chemotherapy including sorafenib. Sorafenib is currently regarded as the first-line chemotherapeutic agent for treatment of advanced HCC following reports of prolonged survival periods in two randomized controlled trials. 1, 2 However, the therapeutic effect of sorafenib is often suboptimal, and most patients experience tumor progression. 3 It is imperative to discover adjunct therapies to enhance the therapeutic effects of sorafenib.
In patients with HCC recurrence after HR or LT, vitamin K administration with or without sorafenib occasionally showed noticeable antitumor effects. 4, 5 However, meta-analyses including a randomized controlled trial
Fig. 1. Selection of patients following hepatic resection (HR) and liver transplantation (LT).
have failed to show the antitumor effects of vitamin K. 6, 7 In a randomized controlled trial, no antitumor or synergistic effects of everolimus were detected in patients with advanced HCC receiving sorafenib. 8 Metformin is a biguanide used for the treatment of type 2 diabetes mellitus (DM). It inhibits cancer cell growth by inducing cell cycle arrest and enhancing apoptosis. [9] [10] [11] [12] A considerable number of studies have suggested that metformin plays a chemopreventive role in other cancers and reduces the risk of HCC, [13] [14] [15] suggesting the antitumor effects of metformin. Recently, it was reported that the combination of metformin and sorafenib suppresses cell proliferation and induces autophagy of HCC in vitro and in vivo by targeting the mammalian target of rapamycin (mTOR) pathway. 16 In addition, metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of HCC in mouse models, in which metformin may potentially enhance the effect of sorafenib to inhibit HCC recurrence and metastasis after HR. 17 Therefore, the present study assessed whether the use of metformin as an adjunct therapy to sorafenib induces synergistic antitumor effects on patients with recurrent HCC following HR or LT. 
MATERIALS AND METHODS

Study design
Patient selection for the LT cohort
The LT database at our institution was also searched to identify patients who underwent LT for HCC over an Finally, 14 patients were assigned to the sorafenib-metformin co-medication group (sorafenib-metformin LT group; group 5), 17 to the sorafenib-insulin co-medication group (sorafenib-insulin LT group; group 6), and 43 to the sorafenib-alone group (non-DM LT control group; group 7) (Fig. 1B) . Patients exposed to both insulin and metformin were assigned to the sorafenib-metformin co-medication group.
To overcome possible selection bias, PSM was conducted between study group 5 and control group 7 using multiple logistic regression analysis and nearest neighbor 
Statistical analysis
RESULTS
Clinical study post HR
The patient selection process for the HR groups is outlined in Fig. 1 . The clinicopathological features of the patients in the sorafenib-metformin HR group (group 1), A comparison between patients in groups 1 and 4 revealed no difference in progression-free survival rates (p=0.078; Fig. 2C ) and overall survival rates (p=0.10; Fig.   2D ) after sorafenib intervention.
Clinical study post LT The patient selection process for the LT groups is outlined in Fig. 1 . The clinicopathological features of the patients in the sorafenib-metformin LT group (group 5), sorafenib-insulin LT group (group 6), non-DM LT control group (group 7), and non-DM LT PSM control group (group 8) are summarized in Table 2 . All patients underwent locoregional therapy for recurrent HCC lesions prior to exposure to sorafenib. The clinicopathological features of patients in groups 5 and 7 were very similar, except for AFP levels. This difference was not detected between patients in groups 5 and 8 after PSM.
During a median follow-up of 13.6 months (range: 3-76 months) after sorafenib administration, death occurred in 62 of the 74 patients (83.8%). The median progressionfree survival period after sorafenib administration was 6.5 months in group 5; 6.1 months in group 6; 6.7 months in group 7; and 6.6 months in group 8 (p=0.99; Fig. 3A ).
Fig. 3.
Comparison of the progression-free survival (A) and overall survival (B) curves after sorafenib administration in liver transplantation groups 5, 6, and 7. Following propensity score matching, the progression-free survival (C) and overall survival (D) curves were compared between LT groups 5 and 8.
The median overall survival after sorafenib therapy was 15.9 months in group 5; 10.8 months in group 6; 11.4 months in group 7; and 10.9 months in group 8 (p=0.89;
Fig. 3B).
A comparison between patients in groups 5 and 8 revealed no difference in progression-free survival rates (p=0.72; Fig. 3C ) and overall survival rates (p=0.58; Fig.   3D ) after sorafenib administration.
DISCUSSION
Sorafenib is a multikinase inhibitor with therapeutic efficacy against HCC. 4 Although sorafenib markedly prolongs the survival of patients with advanced HCC, [8] [9] [10] [11] its potential mechanisms of action that induce clinical bene-
fits are yet to be established. Metformin is a biguanide that inhibits cancer cell growth by inducing cell cycle arrest and enhancing apoptosis, and is reportedly associated with a reduced risk of HCC. [9] [10] [11] [12] [13] [14] [15] Metformin treatment mainly induces the inhibition of mTOR pathway, which plays an important role in the metabolism, growth, and proliferation of cancer cells. 21 Metformin inhibits mTOR pathway via AMP-activated protein kinase (AMPK) activation, which is important for energy homeostasis. 22 Metformin also inhibits the mTOR pathway in an AMPK-independent manner. 23 The This study has a few limitations. Our clinical study was a single-center retrospective study with a limited number of patients. The PSM case-control comparison might not be adequate to overcome the oncological heterogeneity of the study patients. However, a unique strength of this study is that the survival status of all patients was completely followed.
In conclusion, our clinical studies demonstrated no antitumor effects of metformin in patients treated with sorafenib. These findings underscore the need for further high-volume studies to assess the role of metformin in patients exposed to sorafenib for advanced HCC.
